ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 823

Survival of Biopsy Proven Giant Cell Arteritis in Northern Italy: Correlation with Clinical, Laboratory and Histopathological Findings

Luigi Boiardi1, Pierluigi Macchioni2, Francesco Muratore3, Mariagrazia Catanoso2, Alberto Cavazza4, Pamela Mancuso5, Luca Cimino6, Giovanna Restuccia7 and Carlo Salvarani8, 1Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, 2Rheumatology Unit, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 3Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS; Università di Modena e Reggio Emilia, Reggio Emilia, Italy, 4Pathology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, 5Interinstitutional Epidemiology Unit, Azienda USL di Reggio Emilia (Local Health Authority) and Azienda Ospedaliera IRCCS di Reggio Emilia,, Reggio Emilia, Italy, 6Ophthalmology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, 7Rheumatology Unitn, Arcispedale S Maria Nuova, IRCCS, 42100, Italy, 8Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS; Università di Modena e Reggio Emilia, Reggio-Emilia, Italy

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: biopsies, giant cell arteritis, morbidity and mortality, polymyalgia rheumatica and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Vasculitis Poster I: Non-ANCA-Associated and Related Disorders

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: To correlate survival with clinical, laboratory and histopathological findings in a population based cohort of patients with biopsy-proven giant cell arteritis (GCA) living in the Reggio Emilia area during a 26 years period

Methods: In this population-based study, all patients living in the Reggio Emilia area who underwent temporal artery biopsy (TAB) for suspected GCA from January 1, 1986 to December 31, 2012 were identified. A pathologist with expertise in vasculitis and blinded to clinical data and final diagnosis reviewed all TABs. Based on the localization of the inflammation, positive TABs were classified into 4 categories: small vessel vasculitis (SVV), with inflammation limited to small periadventitial vessels devoid of muscular coat; vasa vasorum vasculitis (VVV), with inflammation surrounding the adventitial vasa vasorum; inflammation limited to adventitia (ILA), with inflammation spreading from vasa vasorum to the adventitia without extension to the media; transmural inflammation (TMI), with external elastic lamina disruption and extension of the inflammation to the media. Histopathologic features evaluated were: the severity of inflammation and intimal hyperplasia, both graded on a semiquantitative scale (mild=1, moderate=2 severe=3), the presence of intraluminal acute thrombosis, calcifications, giant cells, fibrinoid necrosis and laminar necrosis. Information about clinical manifestations, laboratory findings, treatment and disease course were collected. Patients were followed from GCA diagnosis to death, migration or December 2013. Survival was estimated with the Kaplan–Meier method. Univariate and multivariate Cox proportional hazards models were used to evaluate potential predictors of survival at diagnosis.

Results: 281 patients (206 female, 73.3%) with biopsy-proven GCA were identified in the study period. 120 patients (84 female, 70%) died during a median follow-up period of 96 (IQR 55, 143) months. At univariate analysis, the presence of polymyalgia rheumatica (PMR) (HR 0.54, 95% CI 0.37-0.79, p=0.002), higher level of hemoglobin (HR 0.84, 95% CI 0.74-0.96, p=0.011) at disease onset, long-term remission (HR 0.47, 95% CI 0.26-0.86, p=0.015) and ILA or VVV at TAB (HR 0.48, 95% CI 0.24-0.97, p=0.041) were associated with lower mortality, while the evidence of large vessel involvement at imaging studies performed at diagnosis was associated with increased mortality (HR 5.84, 95% CI 1.57-21.8, p=0.009). Multivariate analysis confirmed the association between lower mortality and PMR (HR 0.54, 95% CI 0.36-0.81, p=0.003), higher level of hemoglobin (HR 0.83, 95% CI 0.69-0.99, p=0.049) at disease onset, and ILA or VVV at TAB (HR 0.38, 95% CI 0.17-0.82, p=0.014), and between increased mortality and large vessel involvement at imaging studies performed at diagnosis (HR 5.31, 95% CI 1.39-20.26, p=0.014).

Conclusion: PMR at diagnosis and only adventitial inflammation at TAB seem to identify subsets of biopsy-proven GCA patients with more benign disease, while large vessel involvement at diagnosis a subset with reduced survival.


Disclosure: L. Boiardi, None; P. Macchioni, None; F. Muratore, None; M. Catanoso, None; A. Cavazza, None; P. Mancuso, None; L. Cimino, None; G. Restuccia, None; C. Salvarani, None.

To cite this abstract in AMA style:

Boiardi L, Macchioni P, Muratore F, Catanoso M, Cavazza A, Mancuso P, Cimino L, Restuccia G, Salvarani C. Survival of Biopsy Proven Giant Cell Arteritis in Northern Italy: Correlation with Clinical, Laboratory and Histopathological Findings [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/survival-of-biopsy-proven-giant-cell-arteritis-in-northern-italy-correlation-with-clinical-laboratory-and-histopathological-findings/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/survival-of-biopsy-proven-giant-cell-arteritis-in-northern-italy-correlation-with-clinical-laboratory-and-histopathological-findings/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology